Global Coalition on Aging Calls on Policy-Makers to Address Cardiovascular Disease to Promote Healthy Aging

(New York – 1 April 2019) – Today, the Global Coalition on Aging (GCOA), in collaboration with Bayer, released a new report titled Healthy Heart for Healthy Aging: The Need for Awareness, Innovation, and Collaboration in Cardiovascular Health, which examines the cardiovascular health imperative aligned with population aging.

The report highlights the current momentum from the global health community that makes now the opportune time to advance a healthy aging agenda for cardiovascular diseases. The report calls for specific policy actions that will advance ongoing innovation and engage a wide range of stakeholders.

“As the prevalence of cardiovascular diseases rise with the aging of the population – already 1 billion of us over 60 globally and growing to 2 billion by mid-century – now is the time for action,” said Michael W. Hodin, PhD, CEO of GCOA. “We’ve seen incredible innovations in cardiovascular health over the past 50 years, yet CVDs remain the number one cause of death globally.  Unfortunately, this trend will continue with increasing longevity unless policy-makers and public health leaders commit to alleviating the impacts on patients, health systems, economies and society.”

With over 17 million deaths worldwide, CVDs are the largest noncommunicable disease (NCD) by morbidity and mortality. From 1990 to 2016, the number of global, annual CVD deaths increased by more than 40% – from around 12 million to over 17 million – increasing CVDs’ share of total mortality from 27% to 32% of all deaths. CVDs impose an immense burden on individuals and health systems, due to the costs of the diseases and their comorbidities. Yet too often, these diseases are misunderstood as a natural condition of becoming old when in fact proactive attention to prevention, treatments, and care can change the incidence and prevalence of these conditions regardless of age.

“Over the past decades, innovative treatments have contributed to an increase of the average life span. As we continue to see rapidly aging populations around the world, effectively tackling and managing age-related illnesses have become pivotal,” said Dr. Michael Devoy, Chief Medical Officer of Bayer AG. “We have to focus on addressing these unmet needs, by embracing the opportunities around scientific progress and innovation in order to establish a sustainable framework for the future.”

The report calls for action in three areas:

  • Awareness: Meaningful policy action on CVDs must promote awareness and education amongst the public, patients, caregivers, and healthcare professionals to empower healthy choices that reduce risk for CVDs and related health challenges.
  • Innovation: Policy-makers must recognize that innovation moves primarily through incremental advances, so we must accept a research paradigm aligned with this stepwise progression.
  • Collaboration: Effectively addressing the direct and indirect impacts of CVDs will require policies and platforms that engage a wide range of actors, including government agencies, health systems, the private sector, non-profits, multilateral organizations, and advocacy groups.

In recent years, leading global, multilateral, and national institutions and health policy decision-makers – including the WHO, OECD, G20, governments, and others – have recognized the need to address the growing health and economic challenges related to population aging. Landmark public policy initiatives, like WHO’s Decade of Healthy Ageing and the G20 Principles on Silver Economy and Active Aging, have generated global momentum for successful aging. Now, policy-makers must continue this momentum to establish frameworks, programs, and collaborations that realize a sustainable course for healthy and active aging, and CVDs require urgent attention.

“The rise in cardiovascular disease should serve as a major call to action for policy-makers, the health sector, patient advocates, and the public,” said Dr. Holly S. Andersen, MD, Director of Education and Outreach, Ronald O. Perelman Heart Institute. “Innovations in healthcare, medicine, and technology have brought us longer lives, but the next era of innovation is needed as a driver of longer – and healthier – lives.”

To read the full report, click here.

Latest Developments

We keep our members and partners in touch with the most recent updates and opinions in the worldwide dialogue on population longevity and related issues.

GCOA Sign-on Letter to Governor Spanberger: Consequences of Importing Federal Price Caps on Virginians’ Access to Medicine & Healthy Aging Opportunities

Dear Governor Spanberger: We, the undersigned organizations, bring deep, on‑the‑ground experience serving older Americans, patients managing complex and chronic conditions, and their caregivers across Virginia and nationwide. We also have a clear understanding of which policies and programs are effective and where they fall short.

New Report Summarizes State of Expert Opinions on Japan’s Adult Vaccine Policy as Population Shifts Older

The Global Coalition on Aging (GCOA), Health and Global Policy Institute (HGPI), and the Asia-Pacific Consortium for Healthy Aging and Adult Immunization (AP-CHAAI) today announced the launch of Strengthening Vaccine Policy for Healthy Aging and Economic Growth in Japan, a landscape analysis examining the state of vaccine policy in super-aging Japan. Based on a comprehensive review of over 100 policy documents, recommendations, reports, academic papers, and gray literature articles, the report, which was funded by GSK, summarizes the latest academic research and policy discourse around adult vaccines.

WSJ Letter to the Editor: How Flu Vaccine Policies Affect the Economy

Your editorial “Vinay Prasad’s Vaccine Kill Shot” (Review & Outlook, Feb. 12) points out that a recent decision by Mr. Prasad, the leader of the Food and Drug Administration’s vaccine division, will have negative consequences. Mr. Prasad’s decision to reject Moderna’s flu vaccine without even reviewing it is even worse than you describe. Denying us a new, innovative flu vaccine is horrible health policy. Innovation is at risk because, as Moderna’s CEO has said, if the largest market is off limits, investments won’t be made. But the decision will also have economic consequences. Investment in preventive health is critical as our population ages. In its April 2025 World Economic Outlook report, the International Monetary Fund dedicated an entire chapter to the need for healthier longevity as the global population ages.

Joe Biden’s ‘Cancer Moonshot’ May be Derailed by New Policies, Including His Own

For almost a decade, President Biden has championed a bold “cancer moonshot” — an initiative he first launched in 2016, revived early in his administration, and reiterated during this year’s State of the Union. It is a laudable goal, especially for an aging nation where cancer and chronic disease are on the rise. There’s just one problem: Recent federal and state policies are poised to derail the incredible progress made in oncology since 2016. A rash of policies now threatens to limit access and slow progress towards new breakthroughs.

Global Coalition on Aging, Leading G7 Government Officials, Call for Incentivized Antibiotic Innovation

The Global Coalition on Aging (GCOA), in partnership with the Japanese Pharmaceutical Manufacturer’s Association (JPMA), and public health leaders call on G7 governments to fund pull incentives and make “fair share” investments in antibiotic innovation to fight the global antimicrobial resistance (AMR) crisis. GCOA, JPMA, and health and government officials from the European Union, Italy, Japan, and United Kingdom recently convened to discuss how G7 countries must respond. GCOA today published a report detailing takeaways from the closed-door meeting, “The Role of G7 Governments in Global Efforts to Encourage Antimicrobial Development Through a Pull Incentive: Challenges and Collaboration.”

Kishida and Biden Face a Similar Demographic Crisis

Your front page story “Japan wrestles with age-old problem as population declines at record rate” (Report, April 13) and the letter in the same edition from Tim Hill, “A gently declining population is no reason to panic”, both describe what all societies face as they modernise in the 21st century.

2024 AMR Preparedness Index Progress Report Highlights Urgent Need For Global Action Against Antimicrobial Resistance

Today, the Global Coalition on Aging (GCOA) and the Infectious Diseases Society of America (IDSA) launched the 2024 AMR Preparedness Index Progress Report. Released in the lead up to the United Nations General Assembly 2024 High-level Meeting on Antimicrobial Resistance (AMR) this September, the 2024 Progress Report assesses how the eleven largest global economies have advanced on calls to action laid out in the 2021 AMR Preparedness Index.

New Global Analysis Across Five Cities Shows Inequities in Adult Immunization Uptake, Signaling Need to Redesign Local and National Policy Interventions

GSK, in collaboration with the Global Coalition on Aging (GCOA), announced a new report from the IQVIA Institute for Human Data Science (IQVIA Institute). The report, funded by GSK, explores the role of social and structural determinants of health in adult vaccine access and uptake across five global cities with strong data about their aging populations: Bangkok, Thailand; Brussels, Belgium; Chicago, US; Manchester, United Kingdom; and New York City, US.